Logo image of SURF

SURFACE ONCOLOGY INC (SURF) Stock Fundamental Analysis

NASDAQ:SURF - US86877M2098 - Common Stock

1.07 USD
-0.01 (-0.93%)
Last: 9/7/2023, 8:23:11 PM
1.07 USD
0 (0%)
After Hours: 9/7/2023, 8:23:11 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to SURF. SURF was compared to 547 industry peers in the Biotechnology industry. SURF scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SURF is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SURF has reported negative net income.
SURF had a negative operating cash flow in the past year.
SURF had negative earnings in 4 of the past 5 years.
In the past 5 years SURF reported 4 times negative operating cash flow.
SURF Yearly Net Income VS EBIT VS OCF VS FCFSURF Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 0 20M -20M 40M -40M 60M -60M

1.2 Ratios

SURF has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SURF Yearly ROA, ROE, ROICSURF Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 100 200

1.3 Margins

SURF does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SURF Yearly Profit, Operating, Gross MarginsSURF Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 -500 -1K -1.5K -2K -2.5K

More info and screens

5

2. Health

2.1 Basic Checks

SURF does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SURF has more shares outstanding
SURF has a worse debt/assets ratio than last year.
SURF Yearly Shares OutstandingSURF Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M
SURF Yearly Total Debt VS Total AssetsSURF Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M

2.2 Solvency

SURF has an Altman-Z score of -6.54. This is a bad value and indicates that SURF is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -6.54, SURF is doing worse than 72.65% of the companies in the same industry.
There is no outstanding debt for SURF. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.54
ROIC/WACCN/A
WACC9.86%
SURF Yearly LT Debt VS Equity VS FCFSURF Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 3.60 indicates that SURF has no problem at all paying its short term obligations.
SURF's Current ratio of 3.60 is on the low side compared to the rest of the industry. SURF is outperformed by 64.62% of its industry peers.
SURF has a Quick Ratio of 3.60. This indicates that SURF is financially healthy and has no problem in meeting its short term obligations.
SURF has a Quick ratio of 3.60. This is in the lower half of the industry: SURF underperforms 64.10% of its industry peers.
Industry RankSector Rank
Current Ratio 3.6
Quick Ratio 3.6
SURF Yearly Current Assets VS Current LiabilitesSURF Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

SURF shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -18.60%.
The Revenue for SURF has decreased by -100.00% in the past year. This is quite bad
The Revenue has been growing by 18.57% on average over the past years. This is quite good.
EPS 1Y (TTM)-18.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-100%
Revenue growth 3Y24.89%
Revenue growth 5Y18.57%
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, SURF will show a small growth in Earnings Per Share. The EPS will grow by 5.56% on average per year.
SURF is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.55% yearly.
EPS Next Y-41.08%
EPS Next 2Y-21.95%
EPS Next 3Y6.29%
EPS Next 5Y5.56%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-37.88%
Revenue Next 5Y21.55%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
SURF Yearly Revenue VS EstimatesSURF Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M
SURF Yearly EPS VS EstimatesSURF Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SURF reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SURF is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SURF Price Earnings VS Forward Price EarningsSURF Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SURF Per share dataSURF EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-21.95%
EPS Next 3Y6.29%

More info and screens

0

5. Dividend

5.1 Amount

SURF does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SURFACE ONCOLOGY INC

NASDAQ:SURF (9/7/2023, 8:23:11 PM)

After market: 1.07 0 (0%)

1.07

-0.01 (-0.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-02 2023-08-02/bmo
Earnings (Next)10-31 2023-10-31/bmo
Inst Owners1.16%
Inst Owner Change-96.44%
Ins Owners18.04%
Ins Owner Change0%
Market Cap65.08M
Analysts76.36
Price Target2.43 (127.1%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-11.65%
Min EPS beat(2)-33.43%
Max EPS beat(2)10.13%
EPS beat(4)2
Avg EPS beat(4)-2.3%
Min EPS beat(4)-33.43%
Max EPS beat(4)18.07%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-54.6%
EPS NQ rev (1m)1.63%
EPS NQ rev (3m)-5.42%
EPS NY rev (1m)-11.28%
EPS NY rev (3m)-9.63%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-100%
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.32
P/tB 1.32
EV/EBITDA N/A
EPS(TTM)-1.53
EYN/A
EPS(NY)-1.59
Fwd EYN/A
FCF(TTM)-1.38
FCFYN/A
OCF(TTM)-1.37
OCFYN/A
SpS0
BVpS0.81
TBVpS0.81
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 11.76%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.6
Quick Ratio 3.6
Altman-Z -6.54
F-Score2
WACC9.86%
ROIC/WACCN/A
Cap/Depr(3y)15.46%
Cap/Depr(5y)56.41%
Cap/Sales(3y)2.05%
Cap/Sales(5y)3.91%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-18.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-41.08%
EPS Next 2Y-21.95%
EPS Next 3Y6.29%
EPS Next 5Y5.56%
Revenue 1Y (TTM)-100%
Revenue growth 3Y24.89%
Revenue growth 5Y18.57%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-37.88%
Revenue Next 5Y21.55%
EBIT growth 1Y-42.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-372.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-371.18%
OCF growth 3YN/A
OCF growth 5YN/A